Cabergoline and LGD-4033 Interaction
Cabergoline and LGD-4033 have a synergistic interaction with 55% confidence. LGD-4033 supports hormonal recovery from suppression caused by Cabergoline. Standard protocol — begin PCT after the suppressive compound has cleared based on its half-life. Both compounds affect the gonads, so monitoring these systems is recommended.
Compound Profiles
Cabergoline
Dopamine Agonist | Prolactin Management
Cabergoline exerts its effects by acting as a potent agonist at dopamine D2 receptors on lactotroph cells in the anterior pituitary gland. Prolactin secretion is tonically inhibited by hypothalamic dopamine acting on these D2 receptors, and cabergoline mimics this inhibitory signal with high affinity and prolonged duration.
View full profileLGD-4033
Selective Androgen Receptor Modulator | Lean Mass
LGD-4033 binds to the androgen receptor with high affinity (Ki of approximately 1 nM), functioning as a potent and selective agonist in muscle and bone tissue. Like other SARMs, its tissue selectivity is mediated by differential cofactor recruitment: upon binding to the AR, LGD-4033 induces a receptor conformation that preferentially recruits coactivators expressed in skeletal muscle and bone, while showing minimal agonist activity in androgen-sensitive tissues such as the prostate and skin.
View full profileCombined Organ Load
Frequently Asked Questions
Can I take Cabergoline with LGD-4033?
Yes, Cabergoline and LGD-4033 can generally be taken together. LGD-4033 supports hormonal recovery from suppression caused by Cabergoline. Standard protocol — begin PCT after the suppressive compound has cleared based on its half-life.
Is Cabergoline and LGD-4033 safe together?
Based on pharmacological analysis, this combination is considered synergistic. No critical safety flags identified for this pair.
What are the interactions between Cabergoline and LGD-4033?
LGD-4033 supports hormonal recovery from suppression caused by Cabergoline. Standard protocol — begin PCT after the suppressive compound has cleared based on its half-life. This assessment has 55% confidence and is inferred from pharmacological mechanism analysis.
How should I time Cabergoline and LGD-4033?
Cabergoline has a half-life of ~63-69 hours and LGD-4033 has a half-life of ~24-36 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.
This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.